Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | ODC1 | P11926 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA4 | P22748 | 4/20 | 0.35 |
| ▸ | CA6 | P23280 | 4/20 | 0.35 |
| ▸ | CA5A | P35218 | 4/20 | 0.35 |
| ▸ | CA7 | P43166 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA3 | P07451 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | CASP2 | P42575 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL817856 | 1.00 | NFKB1 (0.38) | NFKB1ODC1CA12CA2CA4 | |
| SCHEMBL816414 | 0.93 | NFKB1 (0.43) | NFKB1ODC1CA12CA2CA4 | |
| Hydrochloric Acid SCHEMBL16398251 | 0.90 | NFKB1 (0.40) | NFKB1ODC1CA12CA2CA4 | |
| Water SCHEMBL30354056 | 0.90 | NFKB1 (0.40) | NFKB1ODC1CA12CA2CA4 | |
| SCHEMBL817593 | 0.88 | DNM1 (0.47) | NFKB1CA12CA2CA4CA6 | |
| SCHEMBL5366358 | 0.87 | NFKB1 (0.47) | NFKB1ODC1CA12CA2CA4 | |
| SCHEMBL2357721 | 0.87 | NFKB1 (0.47) | NFKB1ODC1CA12CA2CA4 | |
| SCHEMBL11262880 | 0.87 | ODC1 (0.30) | ODC1 | |
| SCHEMBL318005 | 0.86 | LMNA (0.32) | CA12CA6CA7CA9CA14 | |
| SCHEMBL7093120 | 0.84 | DNM1 (0.50) | NFKB1CA12CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911300-A1 | DRUG DELIVERY SYSTEM | The University of Birmingham (GB) | 2021-11-24 | — | — | EP | claimed |
| EP-3077006-B1 | POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY | WU NIAN (US) | 2020-08-19 | — | — | EP | claimed |
| WO-2020148556-A1 | DRUG DELIVERY SYSTEM | THE UNIVERSITY OF BIRMINGHAM (GB) | 2020-07-23 | — | — | WO | claimed |
| EP-3478249-A1 | STABLE MICROCAPSULE COMPOSITIONS | International Flavors & Fragrances Inc. (US) | 2019-05-08 | — | — | EP | claimed |
| US-10064954-B2 | Polymer-cyclodextrin-lipid conjugates | LIPOSEUTICALS INC | 2018-09-04 | — | — | US | claimed |
| US-9914882-B2 | Reverse emulsion breaker polymers | ECOLAB USA INC. (US) | 2018-03-13 | — | — | US | claimed |
| WO-2018006089-A1 | STABLE MICROCAPSULE COMPOSITIONS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2018-01-04 | — | — | WO | claimed |
| US-20160375150-A1 | POLYMER-CYCLODEXTRIN-LIPID CONJUGATES | LIPOSEUTICALS INC | 2016-12-29 | — | — | US | claimed |
| EP-3077006-A1 | POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY | Wu, Nian (US) | 2016-10-12 | — | — | EP | claimed |
| WO-2016144613-A1 | REVERSE EMULSION BREAKER POLYMERS | ECOLAB USA INC. (US) | 2016-09-15 | — | — | WO | claimed |
| US-8003705-B2 | In situ formation of slowly biodegradable materials; reaction between precursors having electrophilic and nucleophilic functionality; enzymatic and hydrolysis resistance; controlled drug delivery agents, postoperative adhesion prevention, medical device coatings, wound dressings, surgical sealants; kits | INCEPT LLC (US) | 2011-08-23 | — | — | US | claimed |
| EP-2196193-A1 | Hydrogels suitable for use in polyp removal | Tyco Healthcare Group LP (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090324721-A1 | Hydrogels Suitable For Use In Polyp Removal | TYCO HEALTHCARE GROUP LP | 2009-12-31 | — | — | US | claimed |
| US-20080260802-A1 | Biocompatible hydrogels made with small molecule precursors | OCULAR THERAPEUTIX, INC. | 2008-10-23 | — | — | US | claimed |
| EP-1436374-A1 | BENEFIT AGENT DELIVERY SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2004-07-14 | — | — | EP | claimed |
| WO-2003033636-A1 | BENEFIT AGENT DELIVERY SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2003-04-24 | — | — | WO | claimed |
| EP-1246899-A1 | PRO-PERFUME COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2002-10-09 | — | — | EP | claimed |
| CN-1321187-A | Laundry and cleaning compositions | PROCTER & GAMBLE (US) | 2001-11-07 | — | — | CN | claimed |
| WO-2001051599-A1 | PRO-PERFUME COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2001-07-19 | — | — | WO | claimed |
| WO-2001004084-A1 | PROCESS FOR MAKING AMINE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2001-01-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10064954-B2 | Polymer-cyclodextrin-lipid conjugates | CETP, FABP4, PLIN3 | NFKB1 3801/4885ODC1 688/4885CA12 1434/4885 |
| US-20160375150-A1 | POLYMER-CYCLODEXTRIN-LIPID CONJUGATES | CETP, FADS2, FABP4 | NFKB1 3877/4885ODC1 398/4885CA12 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.